News

The European Medicines Agency (EMA) recently adopted a positive opinion extending the use of Stelara (ustekinumab) for children with Crohn’s disease who weigh at least 40kg.

As we embark on a new year, our communication team has been working behind the scenes to bring you closer to the EFCCA community.

EFCCA is proud to partner in the innovative INTERCEPT IHI project, which aims to revolutionise the approach to Crohn’s dvisease by focusing on prevention and early intervention.

EFCCA brought together top researchers, industry experts and patient advocates for a webinar on intestinal fibrosis in IBD

On 20 February 2025, at the 20th ECCO Congress in Berlin, we hosted our conference: "What do IBD patients find important in their treatment? Results from a global Patient Preference survey."

Registrations are open for the 1st GlycanTrigger Patients Symposium, an important event we are co-organising together with the Portuguese Society for Innovation (SPI), focused on collaborative discussions around strategies for predicting and preventing IBD.

We’re excited to present the latest issue of the EFCCA Magazine, now with a refreshed design! Inside, you’ll find an exclusive interview with Professor James Lee, who shares insights on his groundbreaking research into the causes of Inflammatory Bowel Disease (IBD).

EFCCA is excited to introduce a series of webinars, workshops and initiatives to be launched after the summer break.

We are pleased to announce the release of two significant reports that highlight our continuous efforts and achievements in advocating for improved IBD care and quality of life worldwide.

From 7 to 9 June 2024, Brussels hosted the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) General Assembly, representing a significant event for our organisation.